Onsdag 4 November | 11:18:54 Europe / Stockholm
Est. tid*
2027-02-23 08:30 Bokslutskommuniké 2026
2026-10-27 - Kvartalsrapport 2026-Q3
2026-08-11 - Kvartalsrapport 2026-Q2
2026-05-06 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2026-05-05 - Årsstämma
2026-04-28 - Kvartalsrapport 2026-Q1
2026-02-17 - Bokslutskommuniké 2025
2025-11-04 - Kvartalsrapport 2025-Q3
2025-08-12 - Kvartalsrapport 2025-Q2
2025-05-14 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2025-05-13 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-03-04 - Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-08-13 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2024-05-14 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-03-05 - Bokslutskommuniké 2023
2023-10-17 - Kvartalsrapport 2023-Q3
2023-08-15 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-05-17 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2023-05-16 - Årsstämma
2023-03-07 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-16 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2022-05-24 - Årsstämma
2022-05-03 - Kvartalsrapport 2022-Q1
2022-03-08 - Bokslutskommuniké 2021
2021-11-02 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-25 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2021-05-24 - Årsstämma
2021-05-04 - Kvartalsrapport 2021-Q1
2021-03-08 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-20 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2020-05-19 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-08-12 - Kvartalsrapport 2019-Q2
2019-05-09 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2019-05-08 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-03-19 - Extra Bolagsstämma 2019
2019-02-14 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-15 - Kvartalsrapport 2018-Q2
2018-05-15 - Extra Bolagsstämma 2018
2018-05-15 - Kvartalsrapport 2018-Q1
2018-03-01 - X-dag ordinarie utdelning NEEMS B 0.00 SEK
2018-02-28 - Årsstämma
2018-01-30 - Bokslutskommuniké 2017
2017-05-31 - Extra Bolagsstämma 2017
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neem’s Hill är ett svenskt bolag som utvecklar och marknadsför medicinteknologi baserad på elektrokemoterapi för behandling av cancer. Bolaget erbjuder system och lösningar till kliniker inom onkologi och veterinärmedicin och har verksamhet på internationella marknader, bland annat i Indien och Sydostasien. Bolaget grundades 2015 och har sitt huvudkontor i Lund, Sverige.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Neem's Hill AB: Neem's Hill surpasses 5,000 Animal Care treatments sold as recurring kit sales grow

2026-11-03 11:58:21

Growing treatment kit sales and usage of more than 150 treatments per year among advanced users indicate room for further growth through new installations and increased use within existing clinics.

Neem's Hill AB announces that its Animal Care business has surpassed 5,000 treatments sold globally. This reflects the continued adoption of vetIQure™ Tumour Specific Electroporation (TSE) for veterinary cancer care in small companion animals and horses, and the contribution of recurring treatment kit sales to the business.

The vetIQure business model extends beyond the initial sale of a device to a veterinary clinic. Each treatment requires for safety and quality standards, a single-use treatment kit, generating recurring revenue as clinics integrate the technology into their oncology services.

Growth therefore comes from two complementary sources: placing additional devices in veterinary practices and increasing treatment activity within the existing customer base. As more clinics adopt vetIQure and established users gain experience across suitable indications, treatment kit demand can grow alongside the installed base.

Advanced users are already performing more than 150 treatments annually per clinic. This gives an indication of what may be achievable with clinical experience, appropriate patient selection and integration into everyday practice. It also provides a useful reference for supporting other clinics, while recognising that individual volumes will vary.

Clinical value for veterinary practices

For veterinarians, vetIQure offers an additional tool for treating cancer across a range of indications in small companion animals and horses. It can also help clinics expand their oncology services and offer more treatments within their practice.

Our vision is to bring the same commitment to quality and care to animals as we do to humans. In line with this vision, every vetIQure treatment uses a new, sterile, single-use treatment kit with clean, sharp electrodes, designed to support consistent performance each time a veterinarian treats an animal.

For suitable cases, incorporating vetIQure into the treatment pathway may help reduce the cost of care compared with some alternatives, while allowing clinics to offer an additional treatment service. The clinical and financial value will depend on the individual case and the needs of each practice.

To help customers develop their experience, an experienced vetIQure user hosted an invitation-only webinar for fellow users on November 2, 2026. The session focused on sharing practical experience and approaches to using the technology across different clinical situations and indications. Such exchanges can help users build confidence and identify suitable cases within their own practices.

Building on the installed base

"Surpassing 5,000 Animal Care treatments sold is an encouraging step for us," said Mohan S Frick, CEO of Neem's Hill AB. "Our advanced users are already performing more than 150 treatments per year, which gives us a useful indication of the potential within the installed base, which surpassing our own first estimates. We see room to grow both by reaching new clinics and by helping existing users build their treatment activity. Our focus is on supporting that development through clinical experience and close contact with our customers. We believe this can contribute to more consistent recurring revenue over time, while helping clinics offer valuable cancer care to more animals."